Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

BACKGROUND. Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs) that occur in vemurafenib-treated patients, including cutaneou...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Lacouture, Mario E., Duvic, Madeleine, Hauschild, Axel, Prieto, Victor G., Robert, Caroline, Schadendorf, Dirk, Kim, Caroline C., McCormack, Christopher J., Myskowski, Patricia L., Spleiss, Olivia, Trunzer, Kerstin, Su, Fei, Nelson, Betty, Nolop, Keith B., Grippo, Joseph F., Lee, Richard J., Klimek, Matthew J., Troy, James L., Joe, Andrew K.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2013
Teme:
Melanoma and Cutaneous Malignancies
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607529/
https://ncbi.nlm.nih.gov/pubmed/23457002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0333
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki